Lonza to manufacture Alector’s mAb drug candidates for Ph I trial 09-May-2019 By Maggie Lynch Lonza will provide manufacturing for Alector’s Phase I drug candidates for neurodegenerative diseases from its Switzerland site, which is expected to be operational by mid-2020.